Bio Affinity Technologies, Inc. BIAF
Institutional shares held
467,790
0
calls
0
puts
Total value of holdings
$626K
$0
calls
$0
puts
Market Cap
$3.65M
2,727,580
Shares Out.
Institutional ownership
17.15%
# of Institutions
15
We take great care to ensure that the data presented and summarized in this overview for bioAffinity Technologies, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding BIAF
View all-
Vanguard Group Inc Valley Forge, PA261KShares$349,5640.0% of portfolio
-
Geode Capital Management, LLC Boston, MA87.2KShares$116,8220.0% of portfolio
-
Captrust Financial Advisors Raleigh, NC27.9KShares$37,3650.0% of portfolio
-
Sheaff Brock Investment Advisors, LLC20KShares$26,8000.0% of portfolio
-
State Street Corp Boston, MA17.6KShares$23,5840.0% of portfolio
-
Northern Trust Corp Chicago, IL13.7KShares$18,3070.0% of portfolio
-
Creative Planning Overland Park, KS12.1KShares$16,2070.0% of portfolio
-
Xtx Topco LTD London, X011.3KShares$15,0930.0% of portfolio
-
Ifp Advisors, Inc10KShares$13,4000.0% of portfolio
-
Morgan Stanley New York, NY4.96KShares$6,6470.0% of portfolio
Latest Institutional Activity in BIAF
Top Purchases
Top Sells
About BIAF
bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is based in San Antonio, Texas.
Insider Transactions at BIAF
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 05
2024
|
James Michael Edwards VP and CFO |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+46.74%
|
-
|
|
Jul 01
2024
|
Peter S Knight Director |
BUY
Grant, award, or other acquisition
|
Direct |
33,784
+22.34%
|
-
|
|
Jul 01
2024
|
Gary D Rubin Director |
BUY
Grant, award, or other acquisition
|
Direct |
33,784
+18.73%
|
-
|
|
Jul 01
2024
|
Maria Zannes President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
33,784
+12.19%
|
-
|
|
Jul 01
2024
|
Jamie Platt Director |
BUY
Grant, award, or other acquisition
|
Direct |
33,784
+38.16%
|
-
|
|
Jul 01
2024
|
Roby Joyce Director |
BUY
Grant, award, or other acquisition
|
Direct |
33,784
+33.65%
|
-
|
|
Jul 01
2024
|
Robert A. Anderson Director |
BUY
Grant, award, or other acquisition
|
Direct |
33,784
+17.09%
|
-
|
|
Jul 01
2024
|
Steven Girgenti Executive Chairman |
BUY
Grant, award, or other acquisition
|
Direct |
33,784
+3.07%
|
-
|
|
Jul 01
2024
|
Stuart Diamond Director |
BUY
Grant, award, or other acquisition
|
Direct |
33,784
+25.43%
|
-
|
|
Jun 12
2024
|
Gary D Rubin Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,296
+6.85%
|
-
|
|
Jun 12
2024
|
Robert A. Anderson Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,296
+5.99%
|
-
|
|
Jun 12
2024
|
Peter S Knight Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,296
+9.02%
|
-
|
|
Jun 12
2024
|
Jamie Platt Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,296
+28.35%
|
-
|
|
Jun 12
2024
|
Roby Joyce Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,296
+20.17%
|
-
|
|
Jun 12
2024
|
Maria Zannes President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
8,296
+3.81%
|
-
|
|
Jun 12
2024
|
Steven Girgenti Executive Chairman |
BUY
Grant, award, or other acquisition
|
Direct |
8,296
+0.8%
|
-
|
|
Jun 12
2024
|
Stuart Diamond Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,296
+11.27%
|
-
|
|
Apr 08
2024
|
Maria Zannes President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
28,264
-12.32%
|
$56,528
$2.65 P/Share
|
|
Apr 08
2024
|
Maria Zannes President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
64,848
+22.03%
|
$64,848
$1.16 P/Share
|
|
Apr 04
2024
|
Timothy P Zannes Secretary, EVP, Gen. Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
29,031
-38.63%
|
$58,062
$2.58 P/Share
|
Last 12 Months Summary
Buy / Acquisition
960K
Shares
From
17
Insiders
| Grant, award, or other acquisition | 700K shares |
|---|---|
| Exercise of conversion of derivative security | 259K shares |
Sell / Disposition
90.7K
Shares
From
3
Insiders
| Payment of exercise price or tax liability | 90.7K shares |
|---|